Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021

  • By IPP Bureau | January 28, 2022

Financial Results (Q3 FY2022) - QoQ Comparison

The company has reported total income of Rs. 5319.7 crore during the period ended December 31, 2021 as compared to Rs. 5763.2 crore during the period ended September 30, 2021.

The company has posted net profit of Rs. 706.5 crore for the period ended December 31, 2021 as against net profit of Rs. 992 crores for the period ended September 30, 2021.

Financial Results (Q3 FY2022) - YoY Comparison

The company has reported a total income of Rs. 5319.7 crore during the period ended December 31, 2021 as compared to Rs.4929.6 crore during the period ended December 31, 2020.

The company has posted a net profit of Rs.706.5 crore for the period ended December 31, 2021 as against a net profit of Rs.19.8 crore for the period ended December 31, 2020.

Financial Results (9 Months Ended FY2022) - YoY Comparison

The company has reported total income of Rs. 16002.3 crores during the nine-month period ended December 31, 2021 as compared to Rs.14243.8 crores during the nine-month period ended December 31, 2020.

The company has posted net profit of Rs.2269.3 crores for the nine-month period ended December 31, 2021 as against net profit of Rs.1361.4 crores for the nine-month period ended December 31, 2020.

Commenting on the results, Co-chairman & MD, G V Prasad said “We delivered a steady performance in Q3 with healthy EBITDA and strong cash generation, while continuing to invest in building a pipeline of products across businesses. I am pleased that our early adoption and consistency in furthering our sustainability agenda have been recognised with prestigious awards in the last few months. ESG will remain a key focus area for us.”

 

 

Upcoming E-conference

Other Related stories

Startup

Digitization